Physician profile
Javed Suleman
NPI 1861554560
$8,281.22
in general payments reported to CMS, 2019-2025
29 companies · $624 in 2025
The $624 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,098 · 2020: $847 · 2021: $1,623 · 2022: $726 · 2023: $959 · 2024: $1,404 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,986.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,273.73 | 2021-2024 | Dragonfly Opstar, Pressurewire, Xience Skypoint |
| Astrazeneca Pharmaceuticals Lp | $905.70 | 2019-2024 | Breztri, Farxiga |
| Shockwave Medical, INC | $677.77 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Merck Sharp & Dohme LLC | $603.38 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $528.38 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $490.80 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.56 | 2019-2020 | |
| Medtronic Vascular, INC. | $411.30 | 2019-2020 | |
| Glaxosmithkline, LLC. | $374.15 | 2021-2024 | Arexvy |
| Philips North America LLC | $338.90 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $295.13 | 2024-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $244.39 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $215.41 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $180.76 | 2019 | |
| Medtronic, INC. | $170.38 | 2023 | Hawkone |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $149.18 | 2025 | Voquezna |
| Insmed, INC. | $124.72 | 2019 | |
| Neurocrine Biosciences, INC. | $124.70 | 2019 | |
| Gilead Sciences, INC. | $121.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $117.48 | 2019-2023 | Xarelto |
| Chiesi USA, INC. | $109.48 | 2019 | |
| Pfizer INC. | $91.78 | 2019-2021 | |
| Neuronetics, INC. | $85.32 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $81.14 | 2019 | |
| Heartflow, INC. | $34.98 | 2025 | |
| Teleflex LLC | $34.13 | 2023 | Guideliner |
| Scpharmaceuticals INC. | $29.94 | 2025 | |
| Bridgebio Pharma, INC. | $25.53 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $17.89 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javed Suleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.